KLOW 80mg

KLOW 80mg | GHK-Cu · BPC-157 · TB-500 · KPV | Co-lyophilised Research Peptide Blend

Composition: GHK-Cu 50mg + BPC-157 10mg + TB-500 (Thymosin β-4) 10mg + KPV 10mg — 80mg total, co-lyophilised Purity: >99% HPLC per component Appearance: White to off-white powder with slight blue tint (copper content) Storage: –20°C (lyophilised); 2–8°C (reconstituted) Batch: K7392 — Exp. 05/2029

What Is KLOW?

KLOW extends the GLOW three-peptide blend (GHK-Cu + BPC-157 + TB-500) with the addition of KPV, a tripeptide C-terminal fragment of α-MSH (Lys-Pro-Val). The result is a four-component co-lyophilised research blend (80mg total) engaging complementary pathways across ECM remodelling, angiogenic signalling, cytoskeletal dynamics, and NF-κB-associated inflammatory signalling — supplied at greater than 99% purity per component for in-vitro research use.

Component Research Profiles

GHK-Cu (Copper Tripeptide-1) Copper(II)-complexed tripeptide (CAS 89030-95-5) studied for collagen/ECM gene-expression modulation and angiogenic signalling via VEGF-A. See the GLOW blend or standalone GHK-Cu product for the full research profile.

BPC-157 (Body Protection Compound-157) 15-aa pentadecapeptide studied for NO/VEGFR2 angiogenic signalling and cytoprotective pathways in preclinical models. See the standalone BPC-157 product for the full profile.

TB-500 (Thymosin β-4; Tβ4) 43-aa actin-sequestering peptide studied for G-actin/F-actin dynamics and directional cell migration. See the standalone TB-500 product for the full profile.

KPV (Lys-Pro-Val) KPV is a synthetic tripeptide corresponding to the C-terminal tridecapeptide of α-melanocyte-stimulating hormone (α-MSH[11-13]). CAS 67727-97-3; formula C₁₆H₃₀N₄O₄; MW 342.44 g/mol. In cell-based research, KPV has been investigated for its effects on the NF-κB signalling pathway: studies in intestinal epithelial cell lines and macrophage models have examined its capacity to stabilise IκB-α — the principal cytoplasmic inhibitor of NF-κB — attenuating nuclear translocation of NF-κB and associated pro-inflammatory cytokine gene expression. Research has also examined potential interactions with melanocortin receptor subtypes (MC1R, MC3R) in epithelial models, which may contribute to NF-κB pathway modulation via cAMP-dependent mechanisms.

Component Identifiers

Handling & Storage

Store the lyophilised KLOW blend at –20°C in the sealed vial until use. Reconstitute in sterile bacteriostatic water or an appropriate aqueous buffer. Once reconstituted, aliquot and store at 2–8°C; avoid repeated freeze-thaw cycles. The white to off-white appearance with slight blue tint is expected and attributable to GHK-Cu copper content. All handling should comply with standard laboratory safety protocols and applicable institutional guidelines.

Certificate of Analysis

Every component is independently tested and supplied with a Certificate of Analysis confirming purity by HPLC. Batch K7392 — Exp. 05/2029. Available on request and via the Nexyra Lab COA verification portal.

Important Notice

This product is intended strictly for in vitro research and laboratory use only. KLOW blend is not approved for human or veterinary use by the FDA, EMA, or any other regulatory authority. It is not a drug, supplement, or food product. This product must not be administered to humans or animals. By purchasing this product, the buyer confirms they are a qualified researcher and will use the compound solely for lawful scientific research purposes.